Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
VENTOLIN is an oral syrup formulation approved in 1987 by GSK for respiratory indications. The product is a small-molecule bronchodilator delivered via oral route rather than the more common inhaled delivery. It serves patients requiring systemic oral dosing for airway management.
With LOE approaching and moderate competitive pressure (30), the brand team is likely in transition planning mode, requiring specialists in lifecycle management and generic defense strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants
A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients
Worked on VENTOLIN at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
VENTOLIN represents a mature brand in LOE transition, offering limited new-product career growth but strong opportunities in defensive strategy, generics management, and lifecycle optimization. Working on this product develops expertise in brand management under competitive pressure and post-LOE commercial strategy.